*Looks like they want to kill some patients, so as to kill the drug itself, in favor* *of Gates/Fauci's rushed vaccine.*
*MCM* https://anthraxvaccine.blogspot.com/2020/06/who- trial-using-potentially-fatal.html The Solidarity Trial > <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>is > a WHO-led conglomeration of many national trials of treatments for > Covid-19. > <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> > Per > the WHO > <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> > : > > *As of 3 June 2020, more than 3500 patients have been recruited in 35 > countries, with over 400 hospitals actively recruiting patients. Overall, > over 100 countries have joined or expressed an interest in joining the > trial, and WHO is actively supporting 60 of them...* > > The hydroxychloroquine arm of the Solidarity trials restarted enrolling > patients June 3, after being halted May 25 > <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> > by > WHO Director-General Dr. Tedros Ghebreyesus and the Executive Group of the > Solidarity Trial. (The hydroxychloroquine (HCQ) arm of the trials was > stopped after publication of the Lancet Surgisphere study, which claimed > 35% higher death rates in patients who received hydroxychloroquine, but the > study > was quickly retracted > <https://anthraxvaccine.blogspot.com/2020/05/hydroxychloroquine-keeping-you-updated.html> > when > its authors could not verify that the database existed). > > Below are the drugs being tested in Solidarity > <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments> > : > > ● Remdesivir > ● Hydroxychloroquine > ● Lopinavir with Ritonavir > ● Lopinavir with Ritonavir plus Interferon beta-1a. > > However, the *doses* were not specified on WHO's list of the drugs to be > trialed, nor were they specified, surprisingly, in WHO's 4 person > consultation on chloroquine (CQ) dosing > <https://www.who.int/publications/m/item/informal-consultation-on-the-dose-of-chloroquine-and-hydroxychloroquine-for-the-solidarity-clinical-trial---8-april-2020>, > dated April 8. Instead, the Introduction of the Report of that meeting > notes, > > *"The chloroquine or hydroxychloroquine schedule selected for the trial > includes two oral loading doses (250 mg per tablet CQ or 200 mg per tablet > HCQ), then oral twice-daily maintenance doses for ten days. This meeting > convened to discuss the appropriateness of the selected doses for the > trial."* > > Last week, I was alerted to the fact that India's ICMR, its official > medical research agency, had written > <https://www.newindianexpress.com/nation/2020/may/29/icmr-writes-to-who-disagreeing-with-hcq-assessment-officials-say-international-trial-dosage-four-ti-2149702.html> > to > the WHO, telling WHO that the hydroxychloroquine doses being used in the > Solidarity trial were* 4 times higher *than the doses being used in > India. Then I learned that Singapore has been hesitant to participate in > the WHO trial, due to the hydroxychloroquine dose. > > The UK "Recovery" trial was very similar to, but not part of the > international Solidarity conglomeration of clinical trials. The Recovery > trial ended its HCQ arm on June 4, reporting no benefit > <https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19>. > In-hospital mortality of the 1542 patients receiving hydroxychloroquine was > 25.7%, or 396 people. > > The Recovery trial Study Protocol > <https://www.recoverytrial.net/files/recovery-protocol-v6-0-2020-05-14.pdf> > notes > it is funded in part by the Wellcome Trust and the Bill and Melinda Gates > Foundation, and by UK government agencies. The Protocol > <https://www.recoverytrial.net/files/recovery-protocol-v6-0-2020-05-14.pdf>provides > the doses of hydroxychloroquine used, on page 22. Twitter users began to > notice a dosing issue, with hashtag #Recoverygate. > > The HCQ dosing regimen used in the Recovery trial was 12 tablets during > the first 24 hours (800mg initial dose, 800 mg six hours later, 400 mg 6 > hrs later, 400 mg 6 hours later), then 400 mg every 12 hours for 9 more > days. This is *2.4 grams* during the first 24 hours, and a cumulative > dose of 9.2 grams over 10 days. > > The quote from the WHO report on dosing, 4 paragraphs ago, seems to be > deliberately vague regarding the dose used in the Solidarity trial. The > trial is registered <http://www.isrctn.com/ISRCTN83971151> but the > registration fails to specify dosages. > > The registration of the Canadian arm > <https://clinicaltrials.gov/ct2/show/NCT04330690> of the Solidarity > informs us of its dose: 8 tablets during the first 24 hours (800 mg > initial dose, 800 mg 12 hours later) then 400 mg every 12 hours for 9 > more days. This is 1.6 grams during the first 24 hours, and a cumulative > dose of 8.8 grams over 10 days, or only 0.4 grams less than what Recovery > used. The Norwegian arm <https://clinicaltrials.gov/ct2/show/NCT04321616> of > the trial uses dosing identical to Canada. > > Co-Principal Investigators of the Recovery trial, Drs. Peter Horby and > Martin Landray, said they followed the WHO dosing. Landray also claimed > <http://www.francesoir.fr/politique-monde/interview-exclusive-martin-landray-recovery-hydroxychloroquine-game-over-uk>in > an interview that the maximum allowed HCQ dose was "6 or 10 times" the dose > used in Recovery, and that he was using the same hydroxychloroquine dose > used for amebic dysentery. However, the accepted use for HCQ in amebiasis > is only for a liver abscess and only then in pregnancy > <https://www.uptodate.com/contents/extraintestinal-entamoeba-histolytica-amebiasis?search=amebiasis%20hepatic§ionRank=1&usage_type=default&anchor=H4&source=machineLearning&selectedTitle=1~150&display_rank=1#H10>, > when other drugs cannot be used. That dose is 600 mg per day for 2 days, > then 300 mg per day, less than half the Recovery dose. Professor Horby > said that *Paris Soir* misinterpreted Landray's comments, but *Paris Soir* > said > Landray had confirmed > <http://covexit.com/oxford-professor-horby-claims-professor-landray-was-misquoted-france-soir-newspaper-denies-it/> > what > he told them in an email prior to publication. Landray is a very busy man > <https://www.ndph.ox.ac.uk/team/martin-landray>, too busy, apparently, to > look up the proper dose of a drug he gave to over 1500 subjects, who were > randomized to the treatment and had no say in the matter. > > We know that in Brazil, both a high HCQ dose and a low HCQ dose were > trialed, and by April 17 > <https://www.nature.com/articles/d41591-020-00011-3> the high dose arm > was stopped prematurely > <http://covexit.com/oxford-professor-horby-claims-professor-landray-was-misquoted-france-soir-newspaper-denies-it/> > due > to an excess of deaths. The low dose trial continues in Brazil. > > How is the drug hydroxychloroquine normally used? For chronic daily use > in systemic lupus erythematosus or rheumatoid arthritis, patients usually > receive between 200 and 400 mg daily. In acute Q fever, 600 mg daily may > be given at the start of treatment. > > We also know from WHO's March 13 Informal consultation on the potential > role of chloroquine > <https://www.who.int/blueprint/priority-diseases/key-action/RD-Blueprint-expert-group-on-CQ-call-Mar-13-2020.pdf> > that > the Gates Foundation had been studying the drug's pharmacokinetics, and of > the 25 participants at this meeting > <https://www.who.int/blueprint/priority-diseases/key-action/RD-Blueprint-expert-group-on-CQ-call-Mar-13-2020.pdf>, > 5 were from the Gates Foundation. > > The only treatment dose mentioned in the March 13 report > <https://www.who.int/blueprint/priority-diseases/key-action/RD-Blueprint-expert-group-on-CQ-call-Mar-13-2020.pdf> > was > in a paragraph about preventive doses. It said, *"Higher doses would be > considered for treatment, i.e., 10mg/kg base, followed by 5mg/kg twice > daily for seven days." * > > What is the "base"? A 200 mg dose of chloroquine or hydroxychloroquine > contains 155 mg "base" > <https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf> > drug. > > The typical 70 kg person would, if this suggestion had been followed, > receive 700 mg base, or 900 mg of hydroxychloroquine, as a loading dose. > Generally, > a loading dose refers only to a high first dose, not to several high > additional doses. > > What is a toxic dose? All experts agree. "... c*hloroquine has a small > toxic to therapeutic margin,*" according to *Goldfrank's Toxicologic > Emergencies*. It is very safe when used correctly in the right patients, > but a bit more can potentially kill. Prof. Nicholas White, who attended > both WHO consultations on the chloroquines, has mentioned this. > > The WHO hired a consultant to explore the toxicity of hydroxychloroquine > in 1979. The consultant, H. Weniger, looked at 335 episodes of adult > poisoning by chloroquine drugs. Weniger on page 5 notes that a single > dose of 1.5-2 grams of hydroxychloroquine base "may be fatal. > <https://apps.who.int/iris/bitstream/handle/10665/65773/WHO_MAL_79.906.pdf?sequence=1&isAllowed=y> > " > > The Recovery trial used *1.86 grams* hydroxychloroquine base (equal to > 2400 mg of hydroxychloroquine) in the first 24 hours for treatment of > already very ill, hospitalized Covid-19 patients, a potentially lethal > dose. The Canadian and Norwegian trials used 2,000 mg of HCQ, or *1.55 > grams* of HCQ "base." Each trial gave patients a cumulative dose during > the first 24 hours that, when given as a single dose, has been documented > to be lethal. (The drug's half life is about a month, so the cumulative > amount is what's important.) > > The dose used in these trials is not recommended for therapy of any > medical condition, which I confirmed with Goodman and Gilman's Pharmacology > textbook, the drug's label > <https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf>, > and the online subscription medical encyclopedia *UptoDate*. > > Excessive dosing continues to be used in WHO Solidarity trials. These > trials are not testing the benefits of HCQ on Covid-19, but rather testing > whether patients survive toxic, nontherapeutic doses. > > The WHO Solidarity trials, in order to rapidly enroll patients and spare > clinicians a lot of paperwork, collect only limited information on side > effects. No information has yet been provided regarding causes of death in > the completed hydroxychloroquine arm of the Recovery trial, in which 396 > patients died, and it may never be. > > The Solidarity trial design being employed by WHO obscures whether > mortality is due to drug toxicity (in which case, one would expect cause of > death to be arrhythmias such as torsade de points, neuropsychiatric > effects, or hypoglycemia) versus Covid-19. > > In fact, the lack of safety data being collected is downright scary. Here > is a description of the data collected on patients enrolled in Solidarity, > as reported in Science magazine > <https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments> > : > > *The participant has to sign an informed consent form that is scanned and > sent to WHO electronically. After the physician states which drugs are > available at his or her hospital, the website will randomize the patient to > one of the drugs available or to the local standard care for COVID-19.* > > *“After that, no more measurements or documentation are required,” says > Ana Maria Henao Restrepo, a medical officer at WHO’s Emergencies > Programme. Physicians will record the day the patient left the hospital or > died, the duration of the hospital stay, and whether the patient required > oxygen or ventilation, she says. “That’s all.”* > > The WHO report of its meeting on chloroquine dosing > <https://www.who.int/publications/m/item/informal-consultation-on-the-dose-of-chloroquine-and-hydroxychloroquine-for-the-solidarity-clinical-trial---8-april-2020> > states, > > *"Although the preponderance of opinion tilted towards a reasonable > benefit risk profile for the intervention, there was some scepticism about > what was considered a ‘minimalistic safety data collection’ currently > included in the protocol." * > > The high dose regimen being used in these trials has no medical > justification. The trial design, with its limited collection of safety > data, may make it more difficult to identify toxic drug effects, compared > to standard drug trials. This is completely unethical. > > Excessive dosing makes it impossible to assess therapeutic benefit, if > any, of HCQ. > > Giving the drug only to hospitalized patients means that the window of > time during which HCQ would be expected to provide the most benefit, when > viral titers are rising, has passed. > > To sum up: > > 1. HCQ is being given in a non-therapeutic, toxic and potentially lethal > dose. > 2. HCQ is being given too late in the disease course to determine its > value against SAR-CoV-2. > 3. Limited safety data in the Solidarity trials serve to protect trial > investigators and sponsors from disclosure of adverse drug effects, > including death. > 4. I suspect WHO has deliberately withheld information from the public on > hydroxychloroquine dosing in its trial. Fortunately, the information is > discoverable from registries of national trials. > 5. The conclusions to be drawn are frightening: > > a) WHO and other national health agencies, and charities, have > designed huge clinical trials to assure that hydroxychloroquine will fail > to show benefit, presumably to advantage its much more expensive > competitor(s) and vaccines in development. > > b) In so doing, these agencies and charities have conspired to > increase the number of deaths in these trials. > > c) In so doing, they have conspired to deprive billions of people > from potentially benefiting from a safe and inexpensive drug during a major > pandemic. This could lead to prolongation of the pandemic and many > increased cases and deaths. > > -- If you appreciate News From Underground, please consider making a donation — either a one-time gift or a monthly subscription: http://markcrispinmiller.com/support/ Thank you for your support. Ways to unsubscribe: 1) send a blank email to [email protected] PLEASE NOTE: you must unsubscribe using the SAME email with which you subscribed 2) go to http://groups.google.com/group/newsfromunderground and click on the "Unsubscribe or change membership" link in the yellow bar at the top of the page, then click the "Unsubscribe" button on the next page. For more News From Underground, visit http://markcrispinmiller.com --- You received this message because you are subscribed to the Google Groups "News From Underground" group. To unsubscribe from this group and stop receiving emails from it, send an email to [email protected]. To view this discussion on the web visit https://groups.google.com/d/msgid/newsfromunderground/CAGxB6W8mJ6d1oU%2B3ULm%2Bah66p9CAmPLVJ28niaNb7KWXc4POtQ%40mail.gmail.com.
